Supernus Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2018. For the quarter, the company reported total revenue of $102,996,000 compared to $80,398,000 a year ago. Operating earnings was $37,475,000 compared to $22,342,000 a year ago. Earnings before income taxes were $36,371,000 compared to $22,910,000 a year ago. Net earnings was $28,011,000 or $0.52 per diluted share compared to $15,961,000 or $0.29 per diluted share a year ago.

For the nine months, the company reported total revenue of $292,963,000 compared to $213,803,000 a year ago. Operating earnings was $104,589,000 compared to $65,197,000 a year ago. Earnings before income taxes were $101,409,000 compared to $65,558,000 a year ago. Net earnings was $85,100,000 or $1.57 per diluted share compared to $43,626,000 or $0.82 per diluted share a year ago.

For the year 2018, the company is updating its prior guidance. Net product sales in the range of $388 million to $395 million compared to the previously expected range of $385 million to $400 million. Operating earnings in the range of $120 million to $125 million, compared to the previously expected range of $115 million to $125 million.

For the fourth quarter of 2018, the company expects an effective tax rate of approximately 23% to 25%.